Cited by 251Medication Adherence and ComplianceBreast Cancer Treatment StudiesCancer survivorship and care

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Adherence to Endocrine Therapy for Breast Cancer

Chlebowski, Rowan T., Geller, Michelle L.·2006·Oncology

Open this paper in CoChat — free account

Abstract

Purpose: Despite the demonstrated efficacy of long-duration adjuvant tamoxifen and aromatase inhibitor use in breast cancer management, information on adherence to such therapy is limited. Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings. Methods: A systematic search of the PubMed database, augmented by a review of manuscript references and conference proceedings, commonly identified adherence reports in clinical trials but identified only 9 adherence reports in clinical practice settings. Results: In adjuvant breast cancer clinical trials with longer (≧4 years) follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23–28% of the study participants. Adherence to aromatase inhibitors did not differ from adherence to tamoxifen in this setting. In breast cancer prevention trials, tamoxifen was prematurely discontinued by 20–46% of the participants. In clinical practice settings, only 2 reports addressed longer-duration (>4 years) adherence to adjuvant tamoxifen use. In these, tamoxifen was prematurely discontinued by 30–50% of the patients. Conclusion: Adherence to prescribed breast cancer hormone therapy has not received concerted attention. Current, albeit limited, evidence suggests long-term hormone therapy adherence may represent an area limiting optimal breast cancer patient treatment.

Integrity signals

Registry

Crossref · 10.1159/000100444

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Adherence to medication.
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759

Flagged first, then by citations

Show all 50 references

Research works printed but not linked: 1

10.1016%2FS0140-6736%2805%2974803-0 · DOI

Sorted by citations

Items 201–251 of 251

Proteomic signatures identify significantly different inflammatory breast tissue microenvironments depending on mammographic density or estrogen exposure
Heenkenda, M. K., Abrahamsson, A. E., Lundberg, P., & Dabrosin, C. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-01046-4 · Cited by 1
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
Canney, P. A. (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s11835 · Cited by 1
Identification of proteins associated with radiotherapy resistance in breast cancer cells: a combined proteomic and microarray screening approach
Smith, L., Qutob, O., Watson, M., Beavis, A. W., Jameel, J., Welham, K. J., Drew, P. J., Lind, M., & Cawkwell, L. (2008) · Breast Cancer Research · doi:10.1186/bcr1944 · Cited by 1
Quantitative proteomics reveals proteins associated with radiotherapy resistance in breast cancer cells
Smith, L., Potts, D., Qutob, O., Watson, M., Beavis, A. W., Lind, M., Drew, P. J., & Cawkwell, L. (2008) · Breast Cancer Research · doi:10.1186/bcr1943 · Cited by 1
Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage
Kote‐Jarai, Z., Jugurnauth, S. K., Matthews, L., Giddings, I., Bancroft, E. K., Williams, R. D., Girolami, M., Campbell, C., & Eeles, R. A. (2008) · Breast Cancer Research · doi:10.1186/bcr1902 · Cited by 1
Abnormal expression of p53 isoforms can be associated with poor survival in primary breast tumours
Bourdon, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1936 · Cited by 1
Actions of IGF-I are differentially regulated by fatty acids in normal and breast cancer epithelial cells
Perks, C. M., Morrison, A., Zeng, L., Jarrett, C., Hamilton-Shield, J. P., Winters, Z., & Holly, J. (2008) · Breast Cancer Research · doi:10.1186/bcr1923 · Cited by 1
A Review of Endocrine Therapy in Early-stage Breast Cancer
Elayoubi, J. A., Chi, J., Mahmoud, A. A., Alloghbi, A., Assad, H., Shekhar, M. P. V., & Simon, M. S. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000993 · Cited by 1
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
Shinn, E. H., Zahrieh, D. M., DeMichele, A. M., Zdenkowski, N., Lemieux, J., Mao, J. J. J., Bjelic‐Radisic, V., Naughton, M. J., Pfeiler, G., Gelmon, K. A., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07653-2 · Cited by 2
Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trial
Millard, T. A., Turkheimer, L. M., Schlefman, J., Petroni, G. R., Brighton, D., & Showalter, S. L. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf172 · Cited by 1
Adherence to adjuvant hormonal treatment for breast cancer in patients opting for local hospital direct drug distribution in Italy
Rivasi, M., Apollonio, R., Cancian, L., Pilade, T., & Rosa, M. D. (2013) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2012-000244 · Cited by 1
Persistencia a los inhibidores de la aromatasa en la cohorte SIDIAP: mortalidad e influencia de los bifosfonatos
Moncusí, M. P., Vilalta-Carrera, A., Ovejero, D., Aymar, I., Servitja, S., Tusquets, I., Prieto‐Alhambra, D., Díez‐Pérez, A., García‐Giralt, N., & Nogués, X. (2020) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2020000300003 · Cited by 1
Characterization of a cytoskeletal signaling pathway underpinning CD44-initiated, integrin-mediated adhesion of breast cancer cells to bone marrow endothelium
McFarlane, S., Hill, A., Johnston, P., & Waugh, D. (2008) · Breast Cancer Research · doi:10.1186/bcr1920 · Cited by 1
D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity
Aoubala, M. (2008) · Breast Cancer Research · doi:10.1186/bcr1911 · Cited by 1
Primary ductal carcinoma in situmammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways
Farnie, G., Spence, K., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2008) · Breast Cancer Research · doi:10.1186/bcr1978 · Cited by 1
Adherence to hormone therapy in a chemoprevention randomised trial
Atkins, L., Jenkins, V. A., Fallowfield, L. J., & Howell, A. (2008) · Breast Cancer Research · doi:10.1186/bcr1940
Molecular diversity of human breast cancer: clinical and therapeutic implications
Slamon, D. (2008) · Breast Cancer Research · doi:10.1186/bcr1876
C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target
Katz, E., Faratian, D., Bartlett, J., MacLeod, K. G., Pedersen, H., Larionov, A. A., Smith, E., Howell, A., Dixon, J., Evans, E., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr1961
Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor
Bensmail, A., Hutcheson, I. R., Giles, M. G., Gee, J. M. W., & Nicholson, R. I. (2008) · Breast Cancer Research · doi:10.1186/bcr1883
'The sooner the better' or 'too much too soon'? A pilot prospective longitudinal study to evaluate quality of life and body image following immediate latissimus dorsi breast reconstruction
Potter, S., Thomson, H., Fallowfield, L. J., & Winters, Z. (2008) · Breast Cancer Research · doi:10.1186/bcr1972
Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid
Ottewell, P. D., Lefley, D. V., Coleman, R., & Holen, I. (2008) · Breast Cancer Research · doi:10.1186/bcr1965
Cambridge Breast Intensity Modulated Radiotherapy Trial: dosimetry results for 1,139 patients
Coles, C. E., Wilkinson, J., Wilson, C., Burnet, N. G., Wishart, G. C., Twyman, N., Hoole, A. C. F., & Moody, A. (2008) · Breast Cancer Research · doi:10.1186/bcr1958
Chromosomal instability in the pathogenesis and treatment of breast cancer
Venkitaraman, A. R. (2008) · Breast Cancer Research · doi:10.1186/bcr1877
Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models
Polson, E. S., Weidlich, S., Stenhouse, A., & Friedberg, T. (2008) · Breast Cancer Research · doi:10.1186/bcr1934
Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid
Lefley, D. V., Holen, I., Coleman, R., & Ottewell, P. D. (2008) · Breast Cancer Research · doi:10.1186/bcr1964
Investigating h-Prune activation of Wnt signalling in breast cancer
Freeman, J., Zollo, M., & Dale, T. C. (2008) · Breast Cancer Research · doi:10.1186/bcr1899
Identification of genes involved in the formation of lymph node metastasis from human tumour xenograft models of breast cancer
Paon, L., & Eccles, S. (2008) · Breast Cancer Research · doi:10.1186/bcr1921
Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer
Taylor, K. M., Jordan, N., Hiscox, S., Gee, J. M. W., & Nicholson, R. (2008) · Breast Cancer Research · doi:10.1186/bcr1926
Identification of components of the ubiquitin system as targets for therapeutic intervention
Saville, M. K. (2008) · Breast Cancer Research · doi:10.1186/bcr1963
Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers
Hughes, L., Phelps, C., & Rogers, M. J. (2008) · Breast Cancer Research · doi:10.1186/bcr1970
Proapoptotic protein Bid is regulated by phosphorylation during anoikis and the cell cycle
Lindsay, J., & Gilmore, A. P. (2008) · Breast Cancer Research · doi:10.1186/bcr1928
Lymphovascular invasion in breast cancer: improved methods of detection and clinical significance
Mohammed, R., Martin, S. G., Gill, M., Green, A. R., Paish, E. C., & Ellis, I. O. (2008) · Breast Cancer Research · doi:10.1186/bcr1956
Role of CLEVER-1 in breast cancer metastasis
Ammar, A., Mohammed, R., Salmi, M., Pepper, M. S., Paish, E. C., Ellis, I. O., Patel, P. M., & Martin, S. G. (2008) · Breast Cancer Research · doi:10.1186/bcr1919
Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study
Gerty, S., Simmonds, P., Durcan, L., & Eccles, D. (2008) · Breast Cancer Research · doi:10.1186/bcr1955
Surviving breast cancer: can women expect to 'get back to normal'?
Hopwood, P. (2008) · Breast Cancer Research · doi:10.1186/bcr1878
Management of Locoregional and Systemic Recurrence of Breast Cancer: To Stage or Not to Stage and How
Leitch, A. M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3180-6
The QUEST study: a multicentre randomised trial to assess the impact of the type and timing of breast reconstruction on quality of life following mastectomy
Potter, S., & Winters, Z. (2008) · Breast Cancer Research · doi:10.1186/bcr1971
Adesão e persistência à terapia endócrina para o câncer de mama, fatores preditores e resultados relacionados
Brito, C. (2011) · Americanae (AECID Library)
Do menopausal symptoms continue after oral endocrine therapy for breast cancer?
Carpenter, J. S., & Milata, J. L. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000298
The Impact of Access to Cancer Care on Adjuvant Endocrine Therapy Use Among Breast Cancer Survivors in Appalachia
Tan, X., Marshall, V., Camacho, F., Anderson, R. T., & Balkrishnan, R. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.1244
Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study Rachel C. SheltonGrace Clarke HillyerDawn L. HershmanNicole Leoce • Dana H. BovbjergJeanne S. MandelblattLawrence H. Kushi • Lois LameratoS. David NathansonChristine B. AmbrosoneAlfred I. Neugut
Shelton, R. C., Hillyer, G. C., Hershman, D. L., Neugut, A. I., Irving, H., Leoce, N., Bovbjerg, D. H., Mandelblatt, J. S., Kushi, L. H., Lamerato, L. E., et al. (2012)
Endocrine Therapy
Howell, S. J., & Howell, A. (2010) · Springer eBooks · doi:10.1007/978-3-540-69743-5_18
Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor‐Papadimitriou, J., Burchell, J., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr1881
Personalizing endocrine therapy for breast cancer using MRI
Ragusi, M. A. A.-D. D. (2022) · doi:10.33540/1248
Data from Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Sjöström, M., Chang, S. L., Fishbane, N., Davicioni, E., Hartman, L. W., Holmberg, E. C., Feng, F. Y.-C., Speers, C. W., Pierce, L. J., Malmström, P., et al. (2023) · doi:10.1158/1078-0432.c.6528495
Effective Ki-67 Reduction by Short-Term Administration of Letrozole Before Surgery in (Hormone-Positive) Breast Cancer
Eslami, B., Alipour, S., Golfam, F., Jahanbin, B., & Omranipour, R. (2024) · Iranian journal of pathology · doi:10.30699/ijp.2023.2002772.3118
Changes in Technical Equipment and Patient Perspectives Navigating Towards Enhanced Digitalization in Breast Cancer Across Pre-COVID-19 and Early COVID-19 Eras
Schindler, F., Wuerstlein, R., Schinköthe, T., Debes, A. M., Paysen, C., Harbeck, N., & Eggersmann, T. K. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.08.004 · Cited by 1
Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study
Brandstetter, L., Grau, A., Müller-Reiter, M., Salmen, J., Müller-Nordhorn, J., Beck, N., Heuschmann, P., Störk, S., Wöckel, A., & Reese, J. (2026) · BMC Cancer · doi:10.1186/s12885-026-15641-y
Patient-reported distress and correlates while on adjuvant endocrine therapy following breast cancer treatment among post-menopausal women: a group-based trajectory model analysis
Gavin, K. L., Tiegs, J., Winn, A. N., Makris, V., Neuner, J. M., & Flynn, K. E. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10915-4
Self-Reported Compliance With Adjuvant Endocrine Therapy in Young Women With Hormone Receptor-Positive Early Breast Cancer: A Real-World Study from a Tertiary Cancer Center in India
Trikha, M., Rath, S., Ventrapati, P., BHARGAVA, P. G., Siddiqui, A., Pawar, A., Patil, P., Krishnamurthy, R., Sahay, A., Popat, P. B. T., et al. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.08.003
Estradiol-associated extracellular signaling in the human breast in vivo identifies mast cells as tumor-supportive stromal mediators
Abrahamsson, A., Wang, X., Zhong, W., & Dabrosin, C. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2746847

Authors: Chlebowski, R. T., & Geller, M. L.
Affiliations: The Lundquist Institute (US)
ORCID: Chlebowski, Rowan T.
Venue: Oncology
Publisher: S. Karger AG
Published: 2006
Volume: 71
Issue: 1-2
Pages: 1-9
ISSN: 0030-2414 (ISSN-L)
1423-0232
DOI: 10.1159/000100444
OpenAlex: W1540562253
Cited by: 251
References: 50
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 9 · 2014: 21 · 2013: 14 · 2012: 22
FWCI: 3.00
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords: medication adherence, breast cancer, adjuvant endocrine therapy, tamoxifen, aromatase inhibitors, premature discontinuation, Breast Cancer Prevention Trial
MeSH terms: Administration, Oral, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Patient Compliance, Tamoxifen, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adherence to Endocrine Therapy for Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks